Background Although immune checkpoint inhibitors have revolutionized cancer treatment,
clinical benefit with this class of agents has been limited to a subset of patients. Hence, more …

The mammalian target of rapamycin (mTOR) pathway regulates major processes by
integrating a variety of exogenous cues, including diverse environmental inputs in the tumor …

Breast cancer is the most prevalent malignant tumor and main oncologic cause of mortality
in women. Although most diagnosis of breast pathology is accomplished using hematoxylin …

Gliomas are the most common type of primary brain tumor in adults. High-grade neoplasms
are associated with poor prognoses, whereas low-grade neoplasms are associated with 5 …

Identifying putative biomarkers of clinical outcomes in cancer is crucial for successful
enrichment, and for the selection of patients who are the most likely to benefit from a specific …

Melanoma, a highly heterogeneous tumor, is comprised of a functionally diverse spectrum of
cell phenotypes and subpopulations, including stromal cells in the tumor microenvironment …

The characterization of tumor biology and consequently the identification of prognostic and
predictive biomarkers represent key issues for the translational research in breast cancer …

Background Limited therapeutic options are available for triple-negative breast cancer
(TNBC), emphasizing an urgent need for more effective treatment approaches. The …

Background Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors,
has now evolved into the most promising therapy for cancer patients. However, most of …

The standard treatment for Triple Negative Breast Cancer (TNBC) patients is cytotoxic
chemotherapy, but it is restricted since the duration of response is usually short. Blocking the …